Clinical Trials Planning Studies for Rare Thrombotic and Hemostatic Disorders (U34)

The summary for the Clinical Trials Planning Studies for Rare Thrombotic and Hemostatic Disorders (U34) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Clinical Trials Planning Studies for Rare Thrombotic and Hemostatic Disorders (U34)
	CFDA Number:	93.839
	CFDA Description:	Blood Diseases and Resources Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-HL-12-023
	Document Type:	Grants Notice
	Funding Instrument Type:	Cooperative Agreement
	Posted Date:	May 02, 2011
	Creation Date:	May 02, 2011
	Original Closing Date for Applications:	Oct 17, 2013
	Current Closing Date for Applications:	Oct 17, 2013
	Archive Date:	Nov 17, 2013
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	7,200,000
	Federal Grant Award Ceiling:	225,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Foreign (non-U.S.) components of U.S. Organizations are allowed.
Grant Description: This FOA issued by the National Heart, Lung, and Blood Institute invites applications to obtain critical and necessary support in the planning and development of feasible and well designed multicenter clinical trials focused on rare hemostatic and thrombotic disorders. The Clinical Trials Development Resource for Hematologic Disorders (U24) (RFA-HL-12-016) will provide guidance to investigators on trial design, biostatistics, clinical trial management, and regulatory requirements during the funding period.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-hl-12-023.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Safe and Effective Instruments and Devices for Use in the Neonatal Intensive Care Units (STTR) [R41]; • Safe and Effective Instruments and Devices for Use in the Neonatal Intensive Care Units (SBIR) [R43]...; • Clinical Trials Development Resource for Hematologic Disorders (U24); • Early-Phase Clinical Trials for Blood Cell Therapies (R01); • Clinical Hematology and Transfusion Medicine Research Career Development Program (K12); • IMPROVED THERAPY FOR HEMOPHILIA AND HEREDITARY BLEEDING DISORDERS; • Clinical Hematology Research Career Development Program (K12); • MOLECULAR MECHANISMS UNDERLYING DIAMOND-BLACKFAN ANEMIA AND OTHER CONGENITAL BONE MARROW FAILURE SYN...; • SPECIALIZED CENTERS OF CLINICALLY ORIENTED RESEARCH (SCCOR) IN TRANSFUSION BIOLOGY AND MEDICINE; • MYELODYSPLASTIC SYNDROME (MDS): SEEKING CURE THROUGH DISCOVERY ON PATHOGENESIS AND DISEASE PROGRESSI...